Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Single-neutron states in 133Sn.

Physical review letters

Baumann P, Blomqvist J, Fogelberg B, Hoff P, Huck A, Jading Y, Jokinen A, Jonson B, Knipper A, Kratz K, Kurcewicz W, Lindroos M, Lindroth A, Lovhoiden G, Mach H, Marguier G, Nyman G, Ramdhane M, Sanchez-Vega M, Taylor RB, Thorsteinsen TF, Van Duppen P, Walter G, Wöhr A.
PMID: 10062970
Phys Rev Lett. 1996 Aug 05;77(6):1020-1023. doi: 10.1103/PhysRevLett.77.1020.

No abstract available.

Cite
Baumann P, Blomqvist J, Fogelberg B, et al. Single-neutron states in 133Sn. Phys Rev Lett. 1996;77(6):1020-1023doi: 10.1103/PhysRevLett.77.1020.
Baumann, P., Blomqvist, J., Fogelberg, B., Hoff, P., Huck, A., Jading, Y., Jokinen, A., Jonson, B., Knipper, A., Kratz, K., Kurcewicz, W., Lindroos, M., Lindroth, A., Lovhoiden, G., Mach, H., Marguier, G., Nyman, G., Ramdhane, M., Sanchez-Vega, M., Taylor, R. B., Thorsteinsen, T. F., Van Duppen P, Walter, G., & Wöhr, A. (1996). Single-neutron states in 133Sn. Physical review letters, 77(6), 1020-1023. https://doi.org/10.1103/PhysRevLett.77.1020
Baumann, et al. "Single-neutron states in 133Sn." Physical review letters vol. 77,6 (1996): 1020-1023. doi: https://doi.org/10.1103/PhysRevLett.77.1020
Baumann P, Blomqvist J, Fogelberg B, Hoff P, Huck A, Jading Y, Jokinen A, Jonson B, Knipper A, Kratz K, Kurcewicz W, Lindroos M, Lindroth A, Lovhoiden G, Mach H, Marguier G, Nyman G, Ramdhane M, Sanchez-Vega M, Taylor RB, Thorsteinsen TF, Van Duppen P, Walter G, Wöhr A. Single-neutron states in 133Sn. Phys Rev Lett. 1996 Aug 05;77(6):1020-1023. doi: 10.1103/PhysRevLett.77.1020. PMID: 10062970.
Copy Download .nbib Format: NLM
[No title available]

PhytoKeys

Montesinos-Tubée DB, Tovar C, Iberico-Vela G, Montoya-Quino J, Sanchez-Vega I.
PMID: 32148431
PhytoKeys. 2020 Feb 24;140:47-56. doi: 10.3897/phytokeys.140.47738. eCollection 2020.

A new species from the Northern Peruvian Andes (Cajamarca department),

Cite
Montesinos-Tubée DB, Tovar C, Iberico-Vela G, et al. . PhytoKeys. 2020;140:47-56doi: 10.3897/phytokeys.140.47738.
Montesinos-Tubée, D. B., Tovar, C., Iberico-Vela, G., Montoya-Quino, J., & Sanchez-Vega, I. (2020). . PhytoKeys, 14047-56. https://doi.org/10.3897/phytokeys.140.47738
Montesinos-Tubée, Daniel B, et al. "." PhytoKeys vol. 140 (2020): 47-56. doi: https://doi.org/10.3897/phytokeys.140.47738
Montesinos-Tubée DB, Tovar C, Iberico-Vela G, Montoya-Quino J, Sanchez-Vega I. . PhytoKeys. 2020 Feb 24;140:47-56. doi: 10.3897/phytokeys.140.47738. eCollection 2020. PMID: 32148431; PMCID: PMC7052040.
Copy Download .nbib Format: NLM
Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival.

Annals of surgical oncology

Kim JK, Thompson H, Jimenez-Rodriguez RM, Wu F, Sanchez-Vega F, Nash GM, Guillem JG, Paty PB, Wei IH, Pappou EP, Widmar M, Weiser MR, Smith JJ, Garcia-Aguilar J.
PMID: 34601641
Ann Surg Oncol. 2022 Feb;29(2):1172-1179. doi: 10.1245/s10434-021-10877-3. Epub 2021 Oct 03.

BACKGROUND AND OBJECTIVES: Watch-and-wait is variably adopted by surgeons and the impact of this on outcomes is unknown. We compared the disease-free survival and organ preservation rates of locally advanced rectal cancer patients treated by expert colorectal surgeons at...

Cite
Kim JK, Thompson H, Jimenez-Rodriguez RM, et al. Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. Ann Surg Oncol. 2021;29(2):1172-1179doi: 10.1245/s10434-021-10877-3.
Kim, J. K., Thompson, H., Jimenez-Rodriguez, R. M., Wu, F., Sanchez-Vega, F., Nash, G. M., Guillem, J. G., Paty, P. B., Wei, I. H., Pappou, E. P., Widmar, M., Weiser, M. R., Smith, J. J., & Garcia-Aguilar, J. (2022). Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. Annals of surgical oncology, 29(2), 1172-1179. https://doi.org/10.1245/s10434-021-10877-3
Kim, Jin K, et al. "Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival." Annals of surgical oncology vol. 29,2 (2022): 1172-1179. doi: https://doi.org/10.1245/s10434-021-10877-3
Kim JK, Thompson H, Jimenez-Rodriguez RM, Wu F, Sanchez-Vega F, Nash GM, Guillem JG, Paty PB, Wei IH, Pappou EP, Widmar M, Weiser MR, Smith JJ, Garcia-Aguilar J. Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival. Ann Surg Oncol. 2022 Feb;29(2):1172-1179. doi: 10.1245/s10434-021-10877-3. Epub 2021 Oct 03. PMID: 34601641.
Copy Download .nbib Format: NLM
[No title available]

Clinical cancer research : an official journal of the American Association for Cancer Research

Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM.
PMID: 33593884
Clin Cancer Res. 2021 May 01;27(9):2604-2612. doi: 10.1158/1078-0432.CCR-20-4772. Epub 2021 Feb 16.

No abstract available.

Cite
Jones GD, Caso R, Tan KS, et al. . Clin Cancer Res. 2021;27(9):2604-2612doi: 10.1158/1078-0432.CCR-20-4772.
Jones, G. D., Caso, R., Tan, K. S., Mastrogiacomo, B., Sanchez-Vega, F., Liu, Y., Connolly, J. G., Murciano-Goroff, Y. R., Bott, M. J., Adusumilli, P. S., Molena, D., Rocco, G., Rusch, V. W., Sihag, S., Misale, S., Yaeger, R., Drilon, A., Arbour, K. C., Riely, G. J., Rosen, N., Lito, P., Zhang, H., Lyden, D. C., Rudin, C. M., Jones, D. R., Li, B. T., & Isbell, J. M. (2021). . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2604-2612. https://doi.org/10.1158/1078-0432.CCR-20-4772
Jones, Gregory D, et al. "." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2604-2612. doi: https://doi.org/10.1158/1078-0432.CCR-20-4772
Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM. . Clin Cancer Res. 2021 May 01;27(9):2604-2612. doi: 10.1158/1078-0432.CCR-20-4772. Epub 2021 Feb 16. PMID: 33593884; PMCID: PMC8102372.
Copy Download .nbib Format: NLM
The Dairy Cow Slurry Composition Used as Organic Fertilizer Is Influenced by the Level and Origin of the Dietary Protein.

Animals : an open access journal from MDPI

Vicente F, Elouadaf D, Sánchez-Vera A, Soldado A, De La Torre-Santos S, Martínez-Fernández A.
PMID: 34679834
Animals (Basel). 2021 Sep 27;11(10). doi: 10.3390/ani11102812.

Less than 30% of dairy cattle's nitrogen ingested is retained in milk. Therefore, large amounts of nitrogen can be excreted in manure and urine with a potential environmental impact. In addition, some legume forages can be more susceptible to...

Cite
Vicente F, Elouadaf D, Sánchez-Vera A, et al. The Dairy Cow Slurry Composition Used as Organic Fertilizer Is Influenced by the Level and Origin of the Dietary Protein. Animals (Basel). 2021;11(10)doi: 10.3390/ani11102812.
Vicente, F., Elouadaf, D., Sánchez-Vera, A., Soldado, A., De La Torre-Santos, S., & Martínez-Fernández, A. (2021). The Dairy Cow Slurry Composition Used as Organic Fertilizer Is Influenced by the Level and Origin of the Dietary Protein. Animals : an open access journal from MDPI, 11(10), . https://doi.org/10.3390/ani11102812
Vicente, Fernando, et al. "The Dairy Cow Slurry Composition Used as Organic Fertilizer Is Influenced by the Level and Origin of the Dietary Protein." Animals : an open access journal from MDPI vol. 11,10 (2021). doi: https://doi.org/10.3390/ani11102812
Vicente F, Elouadaf D, Sánchez-Vera A, Soldado A, De La Torre-Santos S, Martínez-Fernández A. The Dairy Cow Slurry Composition Used as Organic Fertilizer Is Influenced by the Level and Origin of the Dietary Protein. Animals (Basel). 2021 Sep 27;11(10). doi: 10.3390/ani11102812. PMID: 34679834; PMCID: PMC8532718.
Copy Download .nbib Format: NLM
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

JCO precision oncology

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM.
PMID: 31832578
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12.

PURPOSE: Heterogeneity in tumor mutational burden (TMB) quantification across sequencing platforms limits the application and further study of this potential biomarker of response to immune checkpoint inhibitors (ICI). We hypothesized that harmonization of TMB across platforms would enable integration...

Cite
Vokes NI, Liu D, Ricciuti B, et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019;3doi: 10.1200/PO.19.00171.
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H., Dietlein, F., He, M. X., Margolis, C. A., Elmarakeby, H. A., Girshman, J., Adeni, A., Sanchez-Vega, F., Schultz, N., Dahlberg, S., Zehir, A., Jänne, P. A., Nishino, M., Umeton, R., Sholl, L. M., Van Allen, E. M., Hellmann, M. D., & Awad, M. M. (2019). Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO precision oncology, 3. https://doi.org/10.1200/PO.19.00171
Vokes, Natalie I, et al. "Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.19.00171
Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12. PMID: 31832578; PMCID: PMC6907021.
Copy Download .nbib Format: NLM
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

JAMA oncology

Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA, Kemeny NE, Jarnagin WR.
PMID: 31670750
JAMA Oncol. 2020 Jan 01;6(1):60-67. doi: 10.1001/jamaoncol.2019.3718.

IMPORTANCE: Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients.OBJECTIVE: To evaluate clinical outcomes when HAI chemotherapy...

Cite
Cercek A, Boerner T, Tan BR, et al. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):60-67doi: 10.1001/jamaoncol.2019.3718.
Cercek, A., Boerner, T., Tan, B. R., Chou, J. F., Gönen, M., Boucher, T. M., Hauser, H. F., Do, R. K. G., Lowery, M. A., Harding, J. J., Varghese, A. M., Reidy-Lagunes, D., Saltz, L., Schultz, N., Kingham, T. P., D'Angelica, M. I., DeMatteo, R. P., Drebin, J. A., Allen, P. J., Balachandran, V. P., Lim, K. H., Sanchez-Vega, F., Vachharajani, N., Majella Doyle, M. B., Fields, R. C., Hawkins, W. G., Strasberg, S. M., Chapman, W. C., Diaz, L. A., Kemeny, N. E., & Jarnagin, W. R. (2020). Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA oncology, 6(1), 60-67. https://doi.org/10.1001/jamaoncol.2019.3718
Cercek, Andrea, et al. "Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial." JAMA oncology vol. 6,1 (2020): 60-67. doi: https://doi.org/10.1001/jamaoncol.2019.3718
Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA, Kemeny NE, Jarnagin WR. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020 Jan 01;6(1):60-67. doi: 10.1001/jamaoncol.2019.3718. PMID: 31670750; PMCID: PMC6824231.
Copy Download .nbib Format: NLM
[No title available]

Clinical cancer research : an official journal of the American Association for Cancer Research

Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM.
PMID: 33593884
Clin Cancer Res. 2021 May 01;27(9):2604-2612. doi: 10.1158/1078-0432.CCR-20-4772. Epub 2021 Feb 16.

No abstract available.

Cite
Jones GD, Caso R, Tan KS, et al. . Clin Cancer Res. 2021;27(9):2604-2612doi: 10.1158/1078-0432.CCR-20-4772.
Jones, G. D., Caso, R., Tan, K. S., Mastrogiacomo, B., Sanchez-Vega, F., Liu, Y., Connolly, J. G., Murciano-Goroff, Y. R., Bott, M. J., Adusumilli, P. S., Molena, D., Rocco, G., Rusch, V. W., Sihag, S., Misale, S., Yaeger, R., Drilon, A., Arbour, K. C., Riely, G. J., Rosen, N., Lito, P., Zhang, H., Lyden, D. C., Rudin, C. M., Jones, D. R., Li, B. T., & Isbell, J. M. (2021). . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2604-2612. https://doi.org/10.1158/1078-0432.CCR-20-4772
Jones, Gregory D, et al. "." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2604-2612. doi: https://doi.org/10.1158/1078-0432.CCR-20-4772
Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM. . Clin Cancer Res. 2021 May 01;27(9):2604-2612. doi: 10.1158/1078-0432.CCR-20-4772. Epub 2021 Feb 16. PMID: 33593884; PMCID: PMC8102372.
Copy Download .nbib Format: NLM
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents.

Antioxidants (Basel, Switzerland)

Ortíz de Zárate A, Pérez-Torralba M, Bonet Isidro I, López C, Claramunt RM, Martínez-Casanova D, Sánchez-Vera I, Jiménez-González J, Lavandera JL.
PMID: 34679721
Antioxidants (Basel). 2021 Oct 09;10(10). doi: 10.3390/antiox10101584.

A new series of twenty-three 1,5-benzodiazepin-2(3H)-ones were synthesized and evaluated in the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS), ferric reducing antioxidant power (FRAP), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays as a new chemotype with antioxidant and good drug-like properties. All of the derivatives showed...

Cite
Ortíz de Zárate A, Pérez-Torralba M, Bonet Isidro I, et al. 1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents. Antioxidants (Basel). 2021;10(10)doi: 10.3390/antiox10101584.
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021). 1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents. Antioxidants (Basel, Switzerland), 10(10), . https://doi.org/10.3390/antiox10101584
Ortíz de Zárate, Ana, et al. "1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents." Antioxidants (Basel, Switzerland) vol. 10,10 (2021). doi: https://doi.org/10.3390/antiox10101584
Ortíz de Zárate A, Pérez-Torralba M, Bonet Isidro I, López C, Claramunt RM, Martínez-Casanova D, Sánchez-Vera I, Jiménez-González J, Lavandera JL. 1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents. Antioxidants (Basel). 2021 Oct 09;10(10). doi: 10.3390/antiox10101584. PMID: 34679721; PMCID: PMC8533176.
Copy Download .nbib Format: NLM
Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights.

Nature communications

Alatise OI, Knapp GC, Sharma A, Chatila WK, Arowolo OA, Olasehinde O, Famurewa OC, Omisore AD, Komolafe AO, Olaofe OO, Katung AI, Ibikunle DE, Egberongbe AA, Olatoke SA, Agodirin SO, Adesiyun OA, Adeyeye A, Kolawole OA, Olakanmi AO, Arora K, Constable J, Shah R, Basunia A, Sylvester B, Wu C, Weiser MR, Seier K, Gonen M, Stadler ZK, Kemel Y, Vakiani E, Berger MF, Chan TA, Solit DB, Shia J, Sanchez-Vega F, Schultz N, Brennan M, Smith JJ, Kingham TP.
PMID: 34819518
Nat Commun. 2021 Nov 24;12(1):6821. doi: 10.1038/s41467-021-27106-w.

Understanding the molecular and phenotypic profile of colorectal cancer (CRC) in West Africa is vital to addressing the regions rising burden of disease. Tissue from unselected Nigerian patients was analyzed with a multigene, next-generation sequencing assay. The rate of...

Cite
Alatise OI, Knapp GC, Sharma A, et al. Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nat Commun. 2021;12(1):6821doi: 10.1038/s41467-021-27106-w.
Alatise, O. I., Knapp, G. C., Sharma, A., Chatila, W. K., Arowolo, O. A., Olasehinde, O., Famurewa, O. C., Omisore, A. D., Komolafe, A. O., Olaofe, O. O., Katung, A. I., Ibikunle, D. E., Egberongbe, A. A., Olatoke, S. A., Agodirin, S. O., Adesiyun, O. A., Adeyeye, A., Kolawole, O. A., Olakanmi, A. O., Arora, K., Constable, J., Shah, R., Basunia, A., Sylvester, B., Wu, C., Weiser, M. R., Seier, K., Gonen, M., Stadler, Z. K., Kemel, Y., Vakiani, E., Berger, M. F., Chan, T. A., Solit, D. B., Shia, J., Sanchez-Vega, F., Schultz, N., Brennan, M., Smith, J. J., & Kingham, T. P. (2021). Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature communications, 12(1), 6821. https://doi.org/10.1038/s41467-021-27106-w
Alatise, Olusegun Isaac, et al. "Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights." Nature communications vol. 12,1 (2021): 6821. doi: https://doi.org/10.1038/s41467-021-27106-w
Alatise OI, Knapp GC, Sharma A, Chatila WK, Arowolo OA, Olasehinde O, Famurewa OC, Omisore AD, Komolafe AO, Olaofe OO, Katung AI, Ibikunle DE, Egberongbe AA, Olatoke SA, Agodirin SO, Adesiyun OA, Adeyeye A, Kolawole OA, Olakanmi AO, Arora K, Constable J, Shah R, Basunia A, Sylvester B, Wu C, Weiser MR, Seier K, Gonen M, Stadler ZK, Kemel Y, Vakiani E, Berger MF, Chan TA, Solit DB, Shia J, Sanchez-Vega F, Schultz N, Brennan M, Smith JJ, Kingham TP. Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nat Commun. 2021 Nov 24;12(1):6821. doi: 10.1038/s41467-021-27106-w. PMID: 34819518; PMCID: PMC8613248.
Copy Download .nbib Format: NLM
Precise efficiency calibration of an HPGe detector: source measurements and Monte Carlo calculations with sub-percent precision.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Hardy JC, Iacob VE, Sanchez-Vega M, Effinger RT, Lipnik P, Mayes VE, Willis DK, Helmer RG.
PMID: 11839060
Appl Radiat Isot. 2002 Jan-Feb;56(1):65-9. doi: 10.1016/s0969-8043(01)00168-3.

With the goal of measuring precise gamma-ray intensities for short-lived (< 5 s) accelerator-produced activities, we have calibrated the efficiency of an HPGe detector between 53 and 1836keV to sub-percent precision with a combination of source measurements and Monte...

Cite
Hardy JC, Iacob VE, Sanchez-Vega M, et al. Precise efficiency calibration of an HPGe detector: source measurements and Monte Carlo calculations with sub-percent precision. Appl Radiat Isot. 2002;56(1):65-9doi: 10.1016/s0969-8043(01)00168-3.
Hardy, J. C., Iacob, V. E., Sanchez-Vega, M., Effinger, R. T., Lipnik, P., Mayes, V. E., Willis, D. K., & Helmer, R. G. (2002). Precise efficiency calibration of an HPGe detector: source measurements and Monte Carlo calculations with sub-percent precision. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 56(1), 65-9. https://doi.org/10.1016/s0969-8043(01)00168-3
Hardy, J C, et al. "Precise efficiency calibration of an HPGe detector: source measurements and Monte Carlo calculations with sub-percent precision." Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine vol. 56,1 (2002): 65-9. doi: https://doi.org/10.1016/s0969-8043(01)00168-3
Hardy JC, Iacob VE, Sanchez-Vega M, Effinger RT, Lipnik P, Mayes VE, Willis DK, Helmer RG. Precise efficiency calibration of an HPGe detector: source measurements and Monte Carlo calculations with sub-percent precision. Appl Radiat Isot. 2002 Jan-Feb;56(1):65-9. doi: 10.1016/s0969-8043(01)00168-3. PMID: 11839060.
Copy Download .nbib Format: NLM
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.

Cancer cell

Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, Dancsok AR, Hatzi K, Chen CC, Tschaharganeh DF, Chandwani R, Tasdemir N, Jones KB, Capecchi MR, Vakoc CR, Schultz N, Ladanyi M, Nielsen TO, Lowe SW.
PMID: 30107180
Cancer Cell. 2018 Aug 13;34(2):346-348. doi: 10.1016/j.ccell.2018.07.006.

No abstract available.

Cite
Banito A, Li X, Laporte AN, et al. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell. 2018;34(2):346-348doi: 10.1016/j.ccell.2018.07.006.
Banito, A., Li, X., Laporte, A. N., Roe, J. S., Sanchez-Vega, F., Huang, C. H., Dancsok, A. R., Hatzi, K., Chen, C. C., Tschaharganeh, D. F., Chandwani, R., Tasdemir, N., Jones, K. B., Capecchi, M. R., Vakoc, C. R., Schultz, N., Ladanyi, M., Nielsen, T. O., & Lowe, S. W. (2018). The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer cell, 34(2), 346-348. https://doi.org/10.1016/j.ccell.2018.07.006
Banito, Ana, et al. "The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma." Cancer cell vol. 34,2 (2018): 346-348. doi: https://doi.org/10.1016/j.ccell.2018.07.006
Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, Dancsok AR, Hatzi K, Chen CC, Tschaharganeh DF, Chandwani R, Tasdemir N, Jones KB, Capecchi MR, Vakoc CR, Schultz N, Ladanyi M, Nielsen TO, Lowe SW. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell. 2018 Aug 13;34(2):346-348. doi: 10.1016/j.ccell.2018.07.006. PMID: 30107180; PMCID: PMC6161360.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries